This study is a single-arm, open-label, phase II study of anlotinib combined with radiation
in the treatment of patients with malignant brainstem glioma. Twenty five patients will be
enrolled in the study who is diagonsis with malignant brainstem glioma. The primary objective
includes disease control rate (DCR), the role of antinib combined with radiotherapy in
improving quality of life and 6-month progression-free survival rate. The secondary objective
include overall survival (OS), toxicity profile. Exploratory objectives include the use of
plasma specimens and cerebrospinal fluid (if possible) to detect biomarkers predicting the
efficacy of anlotinib.